ASCO 2025
Advertisement
Dr. Shatsky weighs DESTINY-Breast09 findings and highlights the need to balance efficacy with long-term quality of life.
Emi-Le ADC shows promising activity in B7-H4–positive TNBC and endometrial cancer with a novel auristatin payload.
INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.
ADELA trial explores elacestrant + everolimus for ESR1-mutated breast cancer post-CDK4/6, aiming to boost 2L outcomes.
New ASCENT-04 data could shift first-line care in PD-L1+ TNBC. Dr. Rebecca Shatsky shares real-world insights from ASCO 2025.
HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.
Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Vepdegestrant improves PFS in ESR1-mutant ER+/HER2- breast cancer, offering a well-tolerated oral option post-CDK4/6.
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.
Forty-seven genes were linked to patient survival.
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.
Elinzanetant reduces vasomotor symptoms from endocrine therapy in HR+ breast cancer, with rapid onset and good tolerability.
THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial.
Lower education level was linked to reduced access to mutational testing and clinical trials.
The prospective case series demonstrates the efficacy of the combination in second- and later-line treatment.
Targeted therapies directed toward tumor genotype should be considered in addition to standard-of-care regimens.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.